State of the Scan — August 2026

Precision is winning the argument: this month's data shows the field consolidating around measurable, algorithm-assisted endpoints even as some of last year's hottest storylines cool off.

The big picture

Look across the 3,562 articles indexed this period and one pattern dominates: the research conversation is shifting from "does this drug work" to "how precisely can we predict, measure, and sequence who it works for." The topic-level numbers tell the story bluntly — Artificial Intelligence (+633%), Complete Blood Count analytics (+500%), Measurable Residual Disease (+400%), and Retrospective Analysis (+300%) are all surging together, which is not a coincidence. These are the tools of a field trying to make its endpoints sharper and its patient selection tighter, rather than simply chasing new molecules.

At the same time, some previously hot domains are cooling in ways that look more like maturation than decline. Hematologic malignancies (-30%), early cancer detection (-24%), and AI/ML in clinical diagnostics (-30%) as broad domains are quieter, even as very specific sub-currents within them — CBC diagnostics paired with machine learning (+23%), MRD tracking, ctDNA — are getting louder. Read together, this looks less like fatigue and more like consolidation: the generalist hype is fading while specific, validated applications take root.

What's heating up

• CBC + machine learning in hematology — routine complete blood counts, long a bread-and-butter test, are being re-mined with ML models for earlier signal detection, explaining both the CBC topic explosion and the CBC diagnostics domain's steady +23% climb.
• Measurable residual disease (MRD) as a trial endpoint — MRD status is increasingly used as a fast, precision-graded readout in blood cancers, tightly linked to the cluster on bispecific antibodies and precision sequencing in B-cell malignancies.
• PD-1 blockade and immunotherapy resistance — both up sharply, reflecting a field less interested in whether checkpoint inhibitors work and more focused on why they stop working, driving research into tumor microenvironment remodeling (AMPK/c-MYC signaling, macrophage polarization, CD-pathway crosstalk).
• ctDNA-guided oncology decisions — liquid biopsy is graduating from research tool to clinical lever, exemplified by the CIRCULATE/ALTAIR trial framework guiding real treatment decisions off circulating tumor DNA rather than imaging alone.
• Metabolic reprogramming — up 500%, this connects cardiometabolic work (composite frailty/insulin-resistance indices like AIPFI and TyG-ABSI) with cancer metabolism research, suggesting metabolic mechanism is becoming a shared vocabulary across specialties.

Cooling / quieter

• Rare diseases (-43%) and aging/longevity (-29%) — the steepest domain declines this period, suggesting attention (and possibly funding cycles) rotating toward higher-volume precision oncology and hematology work.
• Classic hematologic malignancy endpoints — hemoglobin, JAK2 status, essential thrombocythemia, median (overall) survival, and clonal evolution all show -100% topic movement, hinting that trial reporting is migrating toward MRD and molecular endpoints rather than traditional survival curves.
• General AI/ML diagnostics as a broad domain (-30%) — even as specific AI applications (CBC-ML, multimodal oncology models) rise, the catch-all "AI in diagnostics" framing is fading, a sign the field wants specificity, not buzzwords.

Themes to watch

Precision endpoints are eating survival curves. The hematology-oncology cluster shows trials increasingly built around molecularly defined patient subsets and intermediate markers — MRD negativity, ctDNA clearance — rather than waiting years for median overall survival data. This is visible in both the rising MRD/ctDNA topics and the simultaneous collapse of "median survival" and "median overall survival" as reported endpoints. Faster, molecularly anchored readouts are becoming the currency of trial success.

BCMA and bispecifics are consolidating multiple myeloma care. Three modalities — ciltacabtagene autoleucel (CAR-T), bispecific antibodies like teclistamab and elranatamab, and antibody-drug conjugates such as belantamab mafodotin — are converging on the same target, BCMA. This isn't diversification for its own sake; it's the field building a full toolkit around one validated axis, mirrored in B-cell malignancy care more broadly, where bispecifics are emerging as genuine chemo-free alternatives.

The tumor microenvironment is the new resistance battleground. Rather than treating checkpoint resistance as a single PD-1/PD-L1 problem, research is fragmenting into mechanism-specific fixes — macrophage polarization via CCL19/PLD1/PLD2, AMPK/c-MYC signaling, and immune-excluded tumor architectures across colorectal, glioblastoma, breast, cervical, and liver cancers. This connects directly to the rising immunotherapy-resistance topic and signals that the next wave of combination therapies will be microenvironment-informed rather than target-agnostic.

Epigenetics and AI are reshaping myeloid malignancy and diagnostics alike. In AML, MDS, and CMML, epigenetic dysregulation is directly informing lower-intensity combination regimens, while separately, explainable AI models (XGBoost, Random Forest, LightGBM, deep learning) are being validated head-to-head against expert clinicians in diagnostics. Both threads share a throughline: mechanistic or algorithmic insight is being translated into decision-grade tools, not just descriptive research.

The through-line

Nothing this month suggests the field is slowing down — it's specializing. The retreat from broad domains like rare disease, generic AI diagnostics, and traditional survival-based hematology reporting isn't a sign of stagnation; it's the flip side of a sharper focus on precision endpoints, molecular residual disease, ctDNA, and target-specific immunotherapy combinations. Pulse readers should expect the next few months to bring more trials measured in MRD-negativity rates and ctDNA clearance than in years-long survival curves — a quieter but more rigorous kind of progress.

Not medical advice.